Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -271.50% is in line with its 5-year average of -295.82%, near the high end of its 5-year range (-1344.45%–-0.03%).
5.45% above its 12-month average of -287.15%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2026 (2026-06-30): -342.31%.
EBITDA MARGIN
-271.50%
EBITDA MARGIN AVG TTM
-287.15%
EBITDA MARGIN AVG 3Y
-295.82%
EBITDA MARGIN AVG 5Y
-295.82%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+5.45%
CURRENT VS 3Y AVG
+8.22%
CURRENT VS 5Y AVG
+8.22%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Intelligent Bio Solutions Inc.
Market Cap
$5.24M
EBITDA Margin
-271.50%
TTM Avg
-287.15%
3Y Avg
-295.82%
5Y Avg
-295.82%
Market Cap
$5.21M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.32M
EBITDA Margin
-2579.35%
TTM Avg
-2579.35%
3Y Avg
-2089.74%
5Y Avg
-2089.74%
Market Cap
$5.08M
EBITDA Margin
-4837.99%
TTM Avg
-4449.42%
3Y Avg
-4104.15%
5Y Avg
-4023.55%
Market Cap
$5.01M
EBITDA Margin
-8.85%
TTM Avg
9.13%
3Y Avg
18.32%
5Y Avg
18.32%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Intelligent Bio Solutions Inc. (INBS) | $5.24M | -271.50% | -287.15% | -295.82% | -295.82% |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | N/A | N/A | N/A | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.21M | N/A | N/A | N/A | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.32M | -2579.35% | -2579.35% | -2089.74% | -2089.74% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.19M | N/A | N/A | N/A | N/A |
| Imunon, Inc. (IMNN)vs › | $5.08M | -4837.99% | -4449.42% | -4104.15% | -4023.55% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.01M | -8.85% | 9.13% | 18.32% | 18.32% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.59M | N/A | N/A | N/A | N/A |
| CalciMedica, Inc. (CALC)vs › | $4.94M | N/A | N/A | N/A | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.69M | -9081.41% | -6199.48% | -3862.58% | -3269.64% |
Gross Margin
48.6%
EBITDA Margin
-271.5%
Operating Margin
-305.0%
Net Margin
-294.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -342.31% |
| 2026-03-31 | -265.57% |
| 2025-12-31 | -259.45% |
| 2025-09-30 | -236.35% |
| 2025-06-30 | -332.07% |
| 2025-03-31 | -332.65% |
| 2024-12-31 | -322.12% |
| 2024-09-30 | -292.45% |
| 2024-06-30 | -346.79% |
| 2024-03-31 | -318.79% |
| 2023-12-31 | -222.63% |
| 2023-09-30 | -278.71% |
| 2023-06-30 | -566.36% |
| 2023-03-31 | -1344.45% |
| 2022-12-31 | -485.82% |
| 2021-06-30 | -0.03% |
| 2021-03-31 | -14.87% |
| 2020-09-30 | -300.36% |
| 2020-06-30 | -115.60% |
| 2020-03-31 | 1880.23% |
| 2019-06-30 | 2512.24% |
| 2017-06-30 | 0.00% |
